Ethosuximide vs Placebo for IBS Pain
Randomized trial found no improvement in abdominal pain and higher discontinuation rates with the calcium channel blocker.
-
By
-
Olivia Anderson
-
February 20, 2026
-
Clinical Scorecard: Ethosuximide vs Placebo for IBS Pain
At a Glance
| Category | Detail |
|---|
| Condition | Irritable Bowel Syndrome (IBS) |
| Key Mechanisms | Inhibition of T-type calcium channels |
| Target Population | Adults meeting Rome IV criteria for IBS |
| Care Setting | Multicenter, double-blind, placebo-controlled randomized clinical trial |
Key Highlights
- Ethosuximide did not significantly reduce abdominal pain compared to placebo.
- Higher discontinuation rates due to adverse events were noted in the ethosuximide group (47% vs 22%).
- Common adverse events included headache, sleep disturbance, fatigue, nausea, abdominal pain, and dizziness.
- No significant differences in secondary endpoints related to IBS severity and quality of life.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of IBS should follow Rome IV criteria.
Management
- Ethosuximide is not recommended for managing abdominal pain in IBS due to lack of efficacy.
Monitoring & Follow-up
- Monitor for adverse events, especially in patients receiving ethosuximide.
Risks
- Increased risk of treatment discontinuation due to adverse events with ethosuximide.
Patient & Prescribing Data
Adults with IBS experiencing moderate to severe abdominal pain.
Ethosuximide is associated with higher adverse events and discontinuation rates.
Clinical Best Practices
- Consider alternative treatments for IBS pain management.
- Evaluate patient tolerance and response to treatment regularly.
References
